Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
Globe Newswire (Thu, 16-Apr 9:15 AM ET)
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
Globe Newswire (Tue, 14-Apr 9:15 AM ET)
Globe Newswire (Thu, 9-Apr 9:15 AM ET)
Globe Newswire (Tue, 17-Mar 4:05 PM ET)
PRNewswire (Fri, 6-Mar 6:40 PM ET)
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Globe Newswire (Mon, 2-Mar 4:05 PM ET)
Myriad Genetics Signals Growth Ahead with Strong Volume Gains and Strategic Test Launches
Market Chameleon (Tue, 24-Feb 5:37 AM ET)
Globe Newswire (Tue, 24-Feb 9:00 AM ET)
Market Chameleon (Tue, 24-Feb 2:31 AM ET)
Diality Appoints Peter Donato as Chief Financial Officer
Business Wire (Tue, 24-Feb 7:05 AM ET)
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Myriad Genetics trades on the NASDAQ stock market under the symbol MYGN.
As of April 24, 2026, MYGN stock price climbed to $4.82 with 66,702 million shares trading.
MYGN has a beta of 2.79, meaning it tends to be more sensitive to market movements. MYGN has a correlation of 0.13 to the broad based SPY ETF.
MYGN has a market cap of $455.22 million. This is considered a Small Cap stock.
Last quarter Myriad Genetics reported $210 million in Revenue and $.04 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.09.
In the last 3 years, MYGN traded as high as $29.30 and as low as $3.76.
The top ETF exchange traded funds that MYGN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
MYGN has underperformed the market in the last year with a return of -33.9%, while the SPY ETF gained +34.1%. In the last 3 month period, MYGN fell short of the market, returning -17.9%, while SPY returned +3.3%. However, in the most recent 2 weeks MYGN has outperformed the stock market by returning +8.6%, while SPY returned +4.5%.
MYGN support price is $4.58 and resistance is $5.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MYGN shares will trade within this expected range on the day.
